- Home
- STWD vs JAZZ Comparison
STWD vs JAZZ Comparison
Compare STWD & JAZZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STWD
- JAZZ
- Stock Information
- Founded
- STWD 2009
- JAZZ 2003
- Country
- STWD United States
- JAZZ Ireland
- Employees
- STWD N/A
- JAZZ N/A
- Industry
- STWD Real Estate Investment Trusts
- JAZZ Biotechnology: Pharmaceutical Preparations
- Sector
- STWD Real Estate
- JAZZ Health Care
- Exchange
- STWD Nasdaq
- JAZZ Nasdaq
- Market Cap
- STWD 6.7B
- JAZZ 6.7B
- IPO Year
- STWD 2009
- JAZZ 2007
- Fundamental
- Price
- STWD $20.05
- JAZZ $107.51
- Analyst Decision
- STWD Buy
- JAZZ Strong Buy
- Analyst Count
- STWD 7
- JAZZ 12
- Target Price
- STWD $21.83
- JAZZ $183.08
- AVG Volume (30 Days)
- STWD 2.0M
- JAZZ 730.8K
- Earning Date
- STWD 08-05-2025
- JAZZ 07-30-2025
- Dividend Yield
- STWD 9.58%
- JAZZ N/A
- EPS Growth
- STWD N/A
- JAZZ 49.21
- EPS
- STWD 0.93
- JAZZ 7.51
- Revenue
- STWD $420,478,000.00
- JAZZ $4,064,808,000.00
- Revenue This Year
- STWD $349.91
- JAZZ $6.05
- Revenue Next Year
- STWD $4.33
- JAZZ $4.68
- P/E Ratio
- STWD $21.48
- JAZZ $14.35
- Revenue Growth
- STWD 7.97
- JAZZ 5.76
- 52 Week Low
- STWD $16.59
- JAZZ $95.49
- 52 Week High
- STWD $21.17
- JAZZ $148.06
- Technical
- Relative Strength Index (RSI)
- STWD 54.08
- JAZZ 45.65
- Support Level
- STWD $19.84
- JAZZ $106.56
- Resistance Level
- STWD $20.24
- JAZZ $109.43
- Average True Range (ATR)
- STWD 0.27
- JAZZ 2.66
- MACD
- STWD -0.04
- JAZZ -0.16
- Stochastic Oscillator
- STWD 56.80
- JAZZ 12.27
About STWD STARWOOD PROPERTY TRUST INC. Starwood Property Trust Inc.
Starwood Property Trust Inc is an American real estate investment trust principally engaged in originating, acquiring, and managing commercial mortgage loans and commercial mortgage-backed securities in the U.S. and Europe. The company organizes its activities into Commercial and Residential Lending Segment, Infrastructure Lending Segment, Property Segment and Investing and Servicing Segment. The company generates the majority of its revenue from the Real estate commercial and residential lending segment, which is engaged in originating, acquiring, financing, and managing commercial first mortgages, and non-agency residential mortgages.
About JAZZ Jazz Pharmaceuticals plc (Ireland)
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.